It is not about advancing, not about approving. It is about: Can it be partnered or sold? Can it attract $$$$$.
7 auto CD19 CAR-Ts approved but only 3 being used.
Now more than 300 allo CAR-Ts in development. Similar to HER2 space. And yet, nobody wants to be part of the allegedly first to become approved allo CAR-T.
Yes, back in 2023 I was in favour of the deal not knowing that there wasn't any other bidder, not knowing that even Precisions biggest sh NOVARTIS preferred to let it go. I trusted the former CHM CEO as she helped to get the deal done. 18 months later, still no partner insight, not even sophies willing to participate in a cap raising.
Her-Vaxx got results better than Herceptin and yet, no sale, no interest at all.
PD1-Vaxx was hailed to be as good as Keytruda and yet, not interest apart of London.
IMU needs funding from a big pharma, only those and not one share to REGAL, JPM & Co. These guys even managed to derail the 6c placement by Lantheus at RAD. Hopper never learns in that regards and todays CHM anns just proved that again.
If the assets are any good Hopper must be removed from the board to attract permanent investments.
IMU Price at posting:
3.6¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)